Sign in

NCT00846742Active, not recruitingPhase 2

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Source: ClinicalTrials.gov · Last updated 26 May 2026

Brief summary (registry, in English)

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
88 (actual)
First submitted
17 Feb 2009
Start date
5 Jun 2009
Primary completion date
11 Jan 2019
Lead sponsor
St. Jude Children's Research Hospital
NCT number
NCT00846742

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 88
  • From 5 Jun 2009 to the primary completion date, 11 Jan 2019
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Intermediate or High risk disease, defined as Stage IB, any III or IV or IA/IIA with "E" lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathy

Who the study is looking for

  • Histologically confirmed, previously untreated Hodgkin lymphoma.
  • Age: Participants must be 21 years of age or younger
  • Stage must be classified as one of the following:
    • Ann Arbor stage IA or IIA with:
  • Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on CXR)
  • < 3 nodal regions involved on the same side of the diaphragm
  • No "E" lesion
  • Female patients who are post-menarchal must have a negative pregnancy test. Patients of reproductive potential must agree to use an effective contraceptive method.
  • Signed informed consent
  • If re-evaluation of a patient's disease shows intermediate risk features, the patient will be removed from the HOD08.

Age in the registry: - to 21 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Dana-Farber Harvard Cancer Center
Coordinator of this site? Confirm its status		BostonUnited StatesUnknown status
St. Jude Children's Research Hospital
Coordinator of this site? Confirm its status		MemphisUnited StatesUnknown status
Packard Children's Hospital, Stanford University
Coordinator of this site? Confirm its status		Palo AltoUnited StatesUnknown status
Children's Hospital of Illinois at OSF St. Francis Medical Center
Coordinator of this site? Confirm its status		PeoriaUnited StatesUnknown status
Rady Children's Hospital - San Diego
Coordinator of this site? Confirm its status		San DiegoUnited StatesUnknown status
Maine Children's Cancer Program (MCCP)
Coordinator of this site? Confirm its status		ScarboroughUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.